<DOC>
	<DOCNO>NCT00214890</DOCNO>
	<brief_summary>Once-daily nucleotide/nucleoside reverse transcriptase inhibitor ( NtRTI/NRTI ) combination form backbone many regimen . Although efficacy data exist tenofovir pyrimidine analogue ( i.e . lamivudine emtricitabine ) , recent clinical data suggest potential interaction tenofovir purine analog ( i.e . abacavir didanosine ) . Specific Aim 1 : To evaluate impact acyclic nucleoside phosphonate , tenofovir ( TDF ) , intracellular metabolism purine nucleoside analog , abacavir ( ABC ) , determinant antiviral potency nucleotide/nucleoside reverse transcriptase inhibitor ( NtRTI/NRTI ) combination . - Hypothesis # 1 : ABC TDF dose together reduced antiviral activity , measure early plasma HIV RNA decay kinetics , drug give alone . - Hypothesis # 2 : ABC dose TDF reduce intracellular concentration , measure ratio carbovir triphosphate ( active metabolite ABC ) deoxyguanosine triphosphate ( endogenous nucleotide ) , compare ABC give alone .</brief_summary>
	<brief_title>Viral Dynamics Pharmacokinetics Abacavir Tenofovir</brief_title>
	<detailed_description>The primary objective study compare virologic potency pharmacology TDF ABC alone combination . Since feasible ethical give mono dual-therapy agent prolonged interval , project design take advantage short term drug exposure . The study performs intensive lab monitor cross-over design compare short course monotherapy dual-therapy . This open-labeled study dual NRTI/NtRTI combination , ABC + TDF , compare ABC TDF monotherapy administer 7 day . A total 20 ARV-naïve subject enrol study . A screening genotype do confirm resistance-associated mutation baseline . Each subject randomize 7-day sequence monotherapy ( ABC TDF ) , four measurement plasma HIV RNA do calculate slope phase one viral decay . Prior initiation nucleoside analogue , PBMCs collect measure baseline expression nucleoside transport enzyme via RT-PCR Western blot analysis . On day 7 8 , serial blood specimen collect plasma intracellular level TDF ABC . The monotherapy sequence follow 35-day washout period . After washout ( day 42 ) , subject initiate dual NRTI/NtRTI therapy sequence additional 7 day . During dual NRTI/NtRTI therapy , , four measurement HIV RNA do calculate slope phase one viral decay . On day 48 49 , serial plasma intracellular level ABC + TDF evaluate . On Day 49 second HIV genotype perform real time . On day 49 , second 7-day sequence , subject receive EFV addition ABC + TDF combination 14 day . Afterwards , second sample PBMCs collect evaluate potential induction suppression nucleoside transport enzyme . Since long-term efficacy TDF + ABC nucleoside backbone yet know , TDF discontinue ( day 63 ) 3TC substitute . Subjects continue HAART portion study additional 46 week EFV + ABC + 3TC .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1 . HIV1 infection , document licensed ELISA test kit confirm Western blot time prior study entry . HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA acceptable alternative confirmatory test . 2 . Antiretroviral naïve define prior therapy . 3 . CD4+ cell count &gt; 200 cells/ mm3 determine site clinical laboratory within 90 day screen . 4 . HIV1 RNA level &gt; 5000 copies/mL obtain site clinical laboratory within 90 day screen . 5 . Laboratory value obtain screen laboratory within 30 day entry : Absolute neutrophil count ( ANC ) ≥ 750/mm3 . Hemoglobin ≥ 8.0 g/dL . Platelet count ≥ 50,000/mm3 . Calculated creatinine clearance ( CrCl ) &gt; 50 mL/min estimate AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase ≤ 5 x ULN . Total bilirubin ≤ 2.5 x ULN . 6 . Negative serum urine pregnancy test within 30 day study entry . 7 . Karnofsky performance score ≥ 70 . 8 . Men woman age ≥ 18 year . 9 . Ability willingness subject give write informed consent . 1 . Any NRTI NNRTIassociated resistance mutation define updated International AIDS SocietyUSA ( IASUSA ) mutation list . 2 . Pregnancy breastfeed . 3 . Active drug alcohol use dependence , opinion investigator , would interfere adherence study requirement . 4 . Urgent need initiate antiretroviral therapy , determine patient 's primary provider . 5 . Serious illness ( require systemic treatment and/or hospitalization ) subject either complete therapy clinically stable therapy , opinion investigator , least 14 day prior study entry . 6 . Use immunomodulator , HIV vaccine , investigational therapy within 30 day study entry . 7 . Use human growth hormone within 30 day prior study entry . 8 . Initiation testosterone anabolic steroid within 30 day prior study entry . ( Exception : Chronic replacement dosages patient 's diagnosed hypogonadism allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>HIV</keyword>
	<keyword>nucleoside pharmacology</keyword>
	<keyword>drug-drug interaction</keyword>
	<keyword>Treatment Naive</keyword>
	<keyword>Drug resistance</keyword>
	<keyword>Drug pharmacokinetics</keyword>
</DOC>